Astrazeneca PLC 6-K, filed Sep 10, 2020
Astrazeneca PLC (AZN)
6-K
2020-09-10
For: 2020-09-10
View Original
Added on
April 02, 2026
About this 6-K
Astrazeneca PLC filed this 6-K on September 10, 2020.
FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of September 2020
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1.
AstraZeneca to list US ADR equity and all US debt securities on
Nasdaq
10 September 2020 07:00 BST
AstraZeneca to list US ADR equity and all US debt securities on
Nasdaq
ADR ticker symbol will remain AZN
AstraZeneca today announced that it will be transferring the
listing of its American Depositary Receipts (ADRs) and its
US-listed debt securities from the New York Stock Exchange (NYSE)
to the Nasdaq Global Select Market (Nasdaq) and Nasdaq Bond
Exchange respectively. The transfers will be effective after market
close on Thursday 24 September 2020.
AstraZeneca ADRs and US-listed debt securities are expected to
commence trading on Nasdaq from Friday 25 September 2020. The ADRs
will continue to be listed under the ticker symbol "AZN". The
Company's primary listing in the UK on the London Stock Exchange
and in Sweden on Nasdaq Stockholm are unaffected by the
move.
Marc Dunoyer, Executive Director and Chief Financial Officer, said:
"The change of stock exchange in the US will reduce overall listing
cost for our equity and debt securities. Further, as a global
science-led, patient-focused biopharmaceutical company, dedicated
to pushing the boundaries of science to deliver life-changing
medicines, we are excited to be joining many of the world's largest
and most innovative companies on Nasdaq."
Thomas Kudsk Larsen, Head of Investor Relations, said: "The move to
Nasdaq for US listing will provide access to stock-market indices
for AstraZeneca's ADR, which is of increasing importance due to the
expanded use of exchange-traded funds as well as index and passive
investment strategies. We continuously focus on improving
conditions for shareholders and potential new investors and the
move to Nasdaq is a logical next step."
Stock-exchange listings
The principal markets for trading in AstraZeneca shares are
currently the London Stock Exchange, Nasdaq Stockholm and the New
York Stock Exchange. Ordinary shares of $0.25 each in AstraZeneca
PLC are listed on the London Stock Exchange and the shareholder
register is maintained by Equiniti Limited. Shares listed on Nasdaq
Stockholm are issued under the Euroclear services agreement by
Euroclear Sweden AB, the Swedish central securities depositary. US
ADRs representing ordinary shares are issued by Deutsche Bank, the
depositary bank, and currently listed on NYSE with intended switch
to Nasdaq on 25 September 2020.
ADR programme
ADRs are US dollar-denominated securities issued by a depositary
bank, representing ownership of the underlying ordinary shares of a
non-US company. AstraZeneca's ADR programme was established in 1999
when Astra AB and Zeneca Group PLC merged. The ADR ratio is 2:1,
meaning two ADRs represent one ordinary share. AstraZeneca's ADRs
trade on NYSE under the symbol "AZN" and will continue to trade
under this symbol after the move to Nasdaq.
Deutsche Bank is the depositary bank for the programme and
undertakes a number of functions including: issuing and cancelling
ADRs; serving as registrar and transfer agent for the ADR and
processing dividend payments for the ADR holders. As at 31 August
2020, 492 million ADRs were outstanding (representing 18.8 per cent
of the share capital of the Company) with an average of 4 million
ADRs traded each day. For more information please
visit https://www.astrazeneca.com/investor-relations/astrazeneca-adr-programme.html.
Debt securities
For details on the Company's debt securities, including outstanding
US dollar-denominated and US-listed debt securities please
visit https://www.astrazeneca.com/investor-relations/debt-investors.html.
AstraZeneca
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development and commercialisation of prescription medicines,
primarily for the treatment of diseases in three therapy areas -
Oncology, Cardiovascular, Renal & Metabolism, and Respiratory
& Immunology. Based in Cambridge, UK, AstraZeneca operates in
over 100 countries and its innovative medicines are used by
millions of patients worldwide. Please
visit astrazeneca.com and
follow the Company on Twitter @AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team, please
click here.
For Media contacts, click here.
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
AstraZeneca
PLC
|
Date:
10 September
2020
|
|
By: /s/
Adrian Kemp
|
|
|
Name:
Adrian Kemp
|
|
|
Title:
Company Secretary
|